Nephropathy in Diabetes

Ludwig Merker; Bernd-Walter Bautsch; Thomas Ebert; Martina Guthoff; Berend Isermann

doi:10.1055/a-1284-6211

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2021; 129(S 01): S60-S63
DOI: 10.1055/a-1284-6211

German Diabetes Association: Clinical Practice Guidelines

Nephropathy in Diabetes

Ludwig Merker

¹MVZ DaVita Dormagen GmbH, Diabetes and Renal Center, Dormagen, Germany

,

Bernd-Walter Bautsch

²Internal Medicine, Catholic Clinics Oberberg, St. Josef Hospital, Engelskirchen, Germany

,

Thomas Ebert

³University Hospital Leipzig, Department of Endocrinology, Nephrology and Rheumatology, Leipzig, Germany

⁴Karolinska Institutet, Department of Clinical Science, Intervention and Technology, Division of Renal Medicine, Stockholm, Schweden, Germany

,

Martina Guthoff

⁵Medical Clinic IV, Diabetology, Endocrinology, Nephrology, University Hospital Tübingen, Germany

,

Berend Isermann

⁶Institute for Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Germany

› Author Affiliations

Abstract

Full Text

References

Literature
1 Mogensen CE. Introduction: Diabetes mellitus and the kidney. Kidney Int 1982; 21: 673-675
2 KDIGO. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1-150
3 Williams B, Mancia G, Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021-3104
4 Buse JB, Wexler DJ, Tsapas A. et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020; 63: 221-228
5 Landgrave R, Aberle J, Birkenfeld AL. et al. Therapy of type 2 diabetes. Diabetol metabolism 2019; 14: S167-S187
6 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020; 41: 111-188
7 Kristensen SL, Rørth R, Jhund PS. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019; 7: 776-785
8 Zelniker TA, Wiviott SD, Raz I. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet 2019; 393: 31-39
9 Perkovic V, Jardine MJ, Neal B. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380: 2295-2306
10 Heerspink HJL, Stefánsson BV, Correa-Rotter R. et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;